A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age

Nicholas Kitchin; Joanna Southern; Rhonwen Morris; Fabienne Hemme; Keith Cartwright; Michael Watson; Elizabeth Miller

doi:10.1016/j.vaccine.2006.02.018

A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age

Nicholas Kitchin^*
, Joanna Southern
, Rhonwen Morris
, Fabienne Hemme
, Keith Cartwright
, Michael Watson
, Elizabeth Miller

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

Abstract

Two hundred forty-one healthy infants were enrolled in an open randomised controlled study of three doses of DTaP-IPV-Hib (Group 1) or DTwP/Hib + OPV (Group 2) at 2, 3 and 4 months of age given concurrently with a meningitis C conjugate vaccine. After each dose, local reactions (any grade) were less common in Group 1 than Group 2 (p < 0.03). Axillary temperature >37.5 °C, decreased feeding, reduced activity, irritability and crying in the week after vaccination were also less common in Group 1 than Group 2 (p < 0.05 for each symptom, all doses combined). Severe local reactions and systemic symptoms were uncommon and occurred equally in both groups. The pentavalent DTaP-IPV-Hib vaccine was less reactogenic than the quadrivalent DTwP-Hib vaccine, as expected when changing from whole cell pertussis (wP) to an acellular pertussis (aP) component.

Original language	English
Pages (from-to)	3964-3970
Number of pages	7
Journal	Vaccine
Volume	24
Issue number	18
DOIs	https://doi.org/10.1016/j.vaccine.2006.02.018
Publication status	Published - 1 May 2006

Bibliographical note

Funding Information:
Funding: The field costs of the study were supported by Sanofi Pasteur MSD. J.S. and R.M. were supported by a grant from the Department of Health Research and Development Directorate (grant number 1217470).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Acellular pertussis
Combination vaccine
Safety

Access to Document

10.1016/j.vaccine.2006.02.018

Fingerprint

Dive into the research topics of 'A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age'. Together they form a unique fingerprint.

Cite this

Kitchin, N., Southern, J., Morris, R., Hemme, F., Cartwright, K., Watson, M., & Miller, E. (2006). A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine, 24(18), 3964-3970. https://doi.org/10.1016/j.vaccine.2006.02.018

Kitchin, Nicholas ; Southern, Joanna ; Morris, Rhonwen et al. / A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. In: Vaccine. 2006 ; Vol. 24, No. 18. pp. 3964-3970.

@article{47dca45ec97546d6a9a657bc8b4e69bb,

title = "A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age",

abstract = "Two hundred forty-one healthy infants were enrolled in an open randomised controlled study of three doses of DTaP-IPV-Hib (Group 1) or DTwP/Hib + OPV (Group 2) at 2, 3 and 4 months of age given concurrently with a meningitis C conjugate vaccine. After each dose, local reactions (any grade) were less common in Group 1 than Group 2 (p < 0.03). Axillary temperature >37.5 °C, decreased feeding, reduced activity, irritability and crying in the week after vaccination were also less common in Group 1 than Group 2 (p < 0.05 for each symptom, all doses combined). Severe local reactions and systemic symptoms were uncommon and occurred equally in both groups. The pentavalent DTaP-IPV-Hib vaccine was less reactogenic than the quadrivalent DTwP-Hib vaccine, as expected when changing from whole cell pertussis (wP) to an acellular pertussis (aP) component.",

keywords = "Acellular pertussis, Combination vaccine, Safety",

author = "Nicholas Kitchin and Joanna Southern and Rhonwen Morris and Fabienne Hemme and Keith Cartwright and Michael Watson and Elizabeth Miller",

note = "Funding Information: Funding: The field costs of the study were supported by Sanofi Pasteur MSD. J.S. and R.M. were supported by a grant from the Department of Health Research and Development Directorate (grant number 1217470). ",

year = "2006",

month = may,

day = "1",

doi = "10.1016/j.vaccine.2006.02.018",

language = "English",

volume = "24",

pages = "3964--3970",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "18",

}

Kitchin, N, Southern, J, Morris, R, Hemme, F, Cartwright, K, Watson, M & Miller, E 2006, 'A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age', Vaccine, vol. 24, no. 18, pp. 3964-3970. https://doi.org/10.1016/j.vaccine.2006.02.018

A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. / Kitchin, Nicholas; Southern, Joanna; Morris, Rhonwen et al.
In: Vaccine, Vol. 24, No. 18, 01.05.2006, p. 3964-3970.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age

AU - Kitchin, Nicholas

AU - Southern, Joanna

AU - Morris, Rhonwen

AU - Hemme, Fabienne

AU - Cartwright, Keith

AU - Watson, Michael

AU - Miller, Elizabeth

N1 - Funding Information: Funding: The field costs of the study were supported by Sanofi Pasteur MSD. J.S. and R.M. were supported by a grant from the Department of Health Research and Development Directorate (grant number 1217470).

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Two hundred forty-one healthy infants were enrolled in an open randomised controlled study of three doses of DTaP-IPV-Hib (Group 1) or DTwP/Hib + OPV (Group 2) at 2, 3 and 4 months of age given concurrently with a meningitis C conjugate vaccine. After each dose, local reactions (any grade) were less common in Group 1 than Group 2 (p < 0.03). Axillary temperature >37.5 °C, decreased feeding, reduced activity, irritability and crying in the week after vaccination were also less common in Group 1 than Group 2 (p < 0.05 for each symptom, all doses combined). Severe local reactions and systemic symptoms were uncommon and occurred equally in both groups. The pentavalent DTaP-IPV-Hib vaccine was less reactogenic than the quadrivalent DTwP-Hib vaccine, as expected when changing from whole cell pertussis (wP) to an acellular pertussis (aP) component.

AB - Two hundred forty-one healthy infants were enrolled in an open randomised controlled study of three doses of DTaP-IPV-Hib (Group 1) or DTwP/Hib + OPV (Group 2) at 2, 3 and 4 months of age given concurrently with a meningitis C conjugate vaccine. After each dose, local reactions (any grade) were less common in Group 1 than Group 2 (p < 0.03). Axillary temperature >37.5 °C, decreased feeding, reduced activity, irritability and crying in the week after vaccination were also less common in Group 1 than Group 2 (p < 0.05 for each symptom, all doses combined). Severe local reactions and systemic symptoms were uncommon and occurred equally in both groups. The pentavalent DTaP-IPV-Hib vaccine was less reactogenic than the quadrivalent DTwP-Hib vaccine, as expected when changing from whole cell pertussis (wP) to an acellular pertussis (aP) component.

KW - Acellular pertussis

KW - Combination vaccine

KW - Safety

UR - https://www.scopus.com/pages/publications/33646493654

U2 - 10.1016/j.vaccine.2006.02.018

DO - 10.1016/j.vaccine.2006.02.018

M3 - Article

C2 - 16517034

AN - SCOPUS:33646493654

SN - 0264-410X

VL - 24

SP - 3964

EP - 3970

JO - Vaccine

JF - Vaccine

IS - 18

ER -

Kitchin N, Southern J, Morris R, Hemme F, Cartwright K, Watson M et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine. 2006 May 1;24(18):3964-3970. doi: 10.1016/j.vaccine.2006.02.018